{
  "docId": "019dd923-5f69-752d-a9b8-7335d4e4bbbd",
  "docSlug": "UazyKuUCi7yVVPL3wJds",
  "documentTitle": "See the pitch deck that Compass Pathways used to raise $80 million and fuel its rise into one of the world's biggest psychedelics companies",
  "authorId": "Pitchdecks",
  "authorName": "Compass Pathways",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.333,
  "pageNumber": 19,
  "pageCount": 28,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a structured list format to break down key assets, clinical development history, and constraints.",
  "elementsJson": [
    "headline_text",
    "bullet_list",
    "callout_box",
    "footnote"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5f69-752d-a9b8-7335d4e4bbbd/19",
  "deckHref": "/decks/019dd923-5f69-752d-a9b8-7335d4e4bbbd",
  "deckJsonHref": "/decks/019dd923-5f69-752d-a9b8-7335d4e4bbbd.json",
  "deckAnchorHref": "/decks/019dd923-5f69-752d-a9b8-7335d4e4bbbd#slide-19",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Despite mixed results, Janssen filed treatment with EMA and FDA (Q3-2018) and noted it is \"confident\" about regulatory approval",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-a290-75b0-a21b-dea287414d92",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.88
      },
      "kind": "disclaimer",
      "text": "* MDD = Major Depressive Disorder, SSRI = Selective Serotonin Reuptake Inhibitor. 1. TRD co-morbidities include: muscle & joint pain (61%), anxiety & panic disorder (50%), fatigue (43%), headache/migraine (35%), sleep disorder (34%)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e1fc8cac-ae5b-41f0-970a-93982e57f4db",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.75,
        "x": 0.2,
        "y": 0.15
      },
      "kind": "list",
      "text": "KEY ASSETS: Same indication (TRD), significant but uncertain efficacy. Populations: 1-5 treatment failures for MDD, MDD with imminent risk of suicide. Intranasal formulation cited as differentiator.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c6546025-e7b8-4965-96bc-a1b920165016",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.75,
        "x": 0.2,
        "y": 0.72
      },
      "kind": "list",
      "text": "CONSTRAINTS: Uncertain efficacy and side effects limit potential future uptake. Despite mixed results, Janssen filed treatment with EMA and FDA and noted it is \"confident\" about regulatory approval.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d1944fe6-23b4-4919-adcc-924a5243e1ab",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.75,
        "x": 0.2,
        "y": 0.35
      },
      "kind": "list",
      "text": "CLINICAL DEVELOPMENT: Mixed Phase III results submitted in 2018. Breakthrough Therapy Designation obtained. Mixed results in TRD Phase III data from 3 short-term and 2 long-term studies.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e4652eff-f20c-4293-aeea-9c23d63a953e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.03
      },
      "kind": "title",
      "text": "Janssen: Despite efficacy uncertainty & co-morbidities of Esketamine, company is confident about regulatory approval",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fb7d2f11-86bd-41aa-bf2a-9d2127df9f59",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "SCQA Framework",
      "slug": "scqa-framework",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "232257f5-db4f-4688-af45-b3ab9ba36f1c",
      "evidence": "The slide presents a clear Situation (efficacy uncertainty & co-morbidities of Esketamine), Complication (uncertain efficacy and side effects), Question (regulatory approval), and Answer (despite mixed results, Janssen is confident about regulatory approval)",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}